fulvestrant has been researched along with decitabine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Davidson, NE; Ferguson, AT; Lapidus, RG | 1 |
| Davidson, NE; Ferguson, AT; Herman, JG; Nelson, WG; Phillips, DL; Yang, X | 1 |
| Cao, L; Gao, H; Gui, S; Li, P; Zhang, Y | 1 |
1 review(s) available for fulvestrant and decitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for fulvestrant and decitabine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression.
Topics: Azacitidine; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 1; Receptors, Estrogen; Receptors, Progesterone; Receptors, Steroid; Transcription Factors; Tumor Cells, Cultured | 1998 |
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Topics: Acetylation; Azacitidine; Breast Neoplasms; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Receptors, Estrogen; RNA, Messenger; Tumor Cells, Cultured | 2001 |
The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
Topics: Animals; Antineoplastic Agents, Hormonal; Azacitidine; beta Catenin; Cell Line, Tumor; Cell Proliferation; Decitabine; Estradiol; Estrogen Receptor alpha; Extracellular Matrix Proteins; Fulvestrant; Intercellular Signaling Peptides and Proteins; Pituitary Neoplasms; Prolactinoma; Rats; Wnt Signaling Pathway | 2014 |